Prediction: This Space Stock Will Outperform SpaceX Over the Next 10 Years

Rocket Lab's revenue has grown roughly 870% since its 2021 public listing, and its $2.36B backlog exceeds trailing revenue of $769M by more than three times. The article expects Neutron's debut in late 2026 or early 2027 and the planned Iridium Communications acquisition to expand Rocket Lab into heavier launches and satellite internet, with a long-term revenue estimate of $10B. However, despite Rocket Lab trading at 56x trailing sales versus SpaceX at 94x, the author argues its $44B market capitalization, expected dilution, and potentially modest space-industry margins leave limited upside at the current share price.

Analysis

The investable issue is not relative P/S, but whether RKLB can convert backlog into positive gross margin and cash flow before funding needs dilute equity holders. Launch remains a low-margin, execution-sensitive business; the higher-value opportunity is vertically integrated spacecraft components and national-security programs, where qualification cycles create stickier revenue and better pricing. A Neutron delay would therefore hurt twice: it postpones revenue while extending the period of development cash burn and equity issuance.

The asserted IRDM transaction is the critical unverified item. If not confirmed by SEC filings and both companies' formal releases, the article should not drive any position: an acquisition of a mature satellite operator would materially change RKLB's leverage, spectrum/network exposure, and capital-allocation profile. If confirmed, IRDM holders may benefit from takeover optionality, but RKLB's equity could face a near-term multiple reset as investors reassess integration risk and the financing required for a capital-intensive network strategy.

Near term, RKLB remains a sentiment and launch-milestone trade; the next 1-3 months should be driven by contract awards, Neutron schedule credibility, and any financing announcement rather than long-duration revenue estimates. Over 6-18 months, the key differentiator versus SPCX is whether RKLB demonstrates repeatable space-systems margins and avoids serial schedule slippage. Consensus may underweight dilution risk: high revenue growth does not support a premium multiple if incremental revenue is purchased through acquisitions, capex, and stock issuance.

Key Decisions for Investors

• No directional trade solely on this article. Verify any RKLB-IRDM transaction through definitive merger documentation, consideration mix, financing commitments, and pro forma leverage before acting.
• For existing RKLB exposure, reduce into strength ahead of Neutron schedule updates; re-add only if management provides a credible first-launch window, funded development plan, and no deterioration in space-systems gross margin. Thesis is falsified by another material schedule slip or an equity raise at a meaningful discount.
• If the IRDM deal is formally announced, evaluate a limited merger-arbitrage long IRDM position only after establishing the spread, regulatory path, and funding certainty; avoid shorting RKLB as a hedge until the exchange ratio or cash consideration is known.
• Watch a relative-value setup: long IRDM / short RKLB only if a transaction is confirmed and RKLB trades at a premium despite incremental net-debt or dilution risk. Exit if synergies are contractually supported, financing is fully committed, or the deal spread narrows below compensation for closing risk.